Edition:
United Kingdom

People: Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

33.41USD
25 Apr 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$33.41
Open
$33.13
Day's High
$34.05
Day's Low
$32.81
Volume
67,779
Avg. Vol
163,542
52-wk High
$54.45
52-wk Low
$27.85

Dobmeier, Eric 

Mr. Eric L. Dobmeier is an Independent Director of the Company. He has served as the Chief Operating Officer of Seattle Genetics, Inc., a biotechnology company, since June 2011. Mr. Dobmeier joined Seattle Genetics in March 2002 and has served in positions of increasing responsibility since then. Prior to joining Seattle Genetics, Mr. Dobmeier was an attorney with the law firms of Venture Law Group and Heller Ehrman LLP, where he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions. Mr. Dobmeier also serves as a director of Stemline Therapeutics, Inc., a public biotechnology company. Mr. Dobmeier received a J.D. from the University of California, Berkeley School of Law and an A.B. in History from Princeton University.

Basic Compensation

Total Annual Compensation, USD 57,500
Restricted Stock Award, USD 96,150
Long-Term Incentive Plans, USD --
All Other, USD 176,789
Fiscal Year Total, USD 330,439

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Isaac Ciechanover

3,366,820

Utpal Koppikar

--

Joseph Newell

1,641,820

Christopher Haqq

3,298,020

Mitchall Clark

1,402,910

Gad Soffer

3,098,040
As Of  31 Dec 2017